Berrin ÇETİNARSLAN, Zeynep CANTÜRK, İlhan TARKUN, Adnan BATMAN, Özlem Zeynep AKYAY, Alev SELEK

Akromegali Hastalarında Hematolojik İndeksler ve Tedavi ile İlişkisi

GİRİŞ ve AMAÇ: Nötrofil/lenfosit oranı (NLR), monosit/lenfosit oranı (MLR), eritrosit dağılım genişliği (RDW) ve trombosit dağılım genişliği (PDW) popüler inflamasyon markerlarıdır. Bu çalışma akromegali hastalarında NLR, MLR, RDW ve PDW'yi değerlendirmeyi ve akromegali tedavisinin bu parametreler üzerindeki etkisini araştırmayı amaçlamaktadır. YÖNTEM ve GEREÇLER: 89 akromegalik hastanın retrospektif NLR, MLR, RDW ve PDW verileri yaş, cinsiyet, hipertansiyon ve diyabet varlığı açısından eşleştirilmiş 60 kontrol grubu ile karşılaştırıldı. Ayrıca hastaların postoperatif sonuçları, medikal tedavi ile hastalık kontrolü sağlanan hastalarda medikal tedavi sonrası sonuçlar ve kontrolsüz hastaların tedavi sonrası verileri preoperatif verileri ile karşılaştırıldı BULGULAR: Ameliyat öncesi aktif akromegali hastalarında NLR ve MLR kontrol grubuna göre anlamlı olarak yüksekti. PDW ve RDW kontrol grubuyla benzerdi. Postoperatif kür sağlanan hastalarda NLR'de anlamlı azalma vardı. MLR'de de azalma sağlandı, ancak fark istatistiksel olarak anlamlı değildi. PDW ve RDW preoperatif değerlerle benzerdi. Remisyon sağlanamayan hastalarda preoperatif değerler medikal tedavi sonrası değerlerle benzerdi. TARTIŞMA ve SONUÇ: NLR, akromegali için yararlı bir inflamasyon belirteci olarak düşünülebilir. Postoperatif kür, akromegali hastalarında inflamasyonda önemli bir azalma sağlayabilir.

Hematological Indices and Their Relationship with Treatment in Acromegaly Patients

INTRODUCTION: Neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), erythrocyte distribution width (RDW) and platelet distribution width (PDW) have been more popular inflammation markers. The present study aims to evaluate NLR, MLR, RDW and PDW in acromegalic patients and to investigate the effect of acromegaly treatment on these parameters. METHODS: NLR, MLR, RDW and PDW values were compared using retrospective data 89 acromegalic patients and 60 controls matched with respect to age, gender, the presence of hypertension and diabetes mellitus. In addition, patients’ postoperative outcomes, outcomes following medical treatment in patients in whom disease control was achieved with medical therapy and post-treatment data of uncontrolled patients were compared using preoperative data. RESULTS: During the preoperative active acromegaly phase, NLR and MLR were significantly higher compared to the control group. PDW and RDW were comparable with the control group. Patients who were cured postoperatively had a significant reduction in NLR. Reduction was also achieved in MLR but the difference was not statistically significant. PDW and RDW were similar with preoperative values. In patients in whom remission could not be achieved, preoperative values and values following medical treatment were comparable. DISCUSSION AND CONCLUSION: NLR can be considered a useful inflammation marker for acromegaly. Postoperative cure can constitute a significant reduction inflammation in acromegaly patients.

PDF

___

1) Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005; 90:4081-4086.
2) Holdaway IM. Excess mortality in acromegaly. Horm Res. 2007; 68: 166-172.
3) Dekkers OM, Biermasz NR, Pereira AM, Romijn JA and Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93: 61-67.
4) Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Alonso AA, Sheppard MC, et al. Mortality in patients with pituitary disease. Endocrine Reviews. 2010; 31: 301-342.
5) Holdaway IM and Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999; 2: 29-41.
6) Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99: 3933–3951.
7) Akbas, EM, Demirtas L, Ozcicek A, Timuroglu A, Bakirci EM, Hamur H, et al. Association of epicardial adipose tissue, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with diabetic nephropathy. Int J Clin Exp Med. 2014; 7: 1794-1801.
8) Demirtas L, Degirmenci H, Akbas EM, Ozcicek A, Timuroglu A, Gurel A, et al. Association of hematological indicies with diabetes, impaired glucose regulation and microvascular complications of diabetes. Int J Clin Exp Med. 2015; 8: 11420–11427.
9) Akyel A, Yayla Ç, Erat M, Çimen T, Doğan M, Açıkel S, et al. Neutrophil-to-lymphocyte ratio predicts hemodynamic significance of coronary artery stenosis. Anatol J Cardiol 2015; 15: 1002-7
10)Oylumlu M, Yıldız A, Oylumlu M, Yuksel M, Polat N, Bilik MZ, et al. Platelet-to-lymphocyte ratio is a predictor of in hospital mortality patients with acute coronary syndrome. Anatol J Cardiol. 2015; 15: 277–283.
11) Mete Ural U, Sehitoglu I, Bayoglu Tekin Y and Kir Sahin F. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2015; 41: 445-8.
12) Raungkaewmanee S, Tangjitgamol S, Manu- sirivithaya S, Srijaipracharoen S and Tha- varamara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012; 23: 265-273.
13) Warimwe GM, Fletcher HA, Olotu A, Agnandji ST, Hill AV, Marsh K, et al. Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS, S malaria vaccine: Analysis of pooled phase II clinical trial data. BMC Med. 2013;21: 184.
14. Akgul E, Tokgozoglu SL, Erbas T, Kabakci T, Aytemir K, Haznedaroglu İ, et al. Evaluation of the Impact of Treatment on Endothelial Function and Cardiac Performance in Acromegaly. Echocardiography. 2010; 27: 990-996.
15. L.Boero, L.Cuniberti, N. Magnani, M. Manavela, V. Yapur, M. Bustos, et al. Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly. Clin Endocrinol (oxf) 2010; 72:654–66
16. Unubol M, Guney E, Ture M, Eryılmaz U. Mean platelet volume and arterial stiffness in patients with acromegaly Anatol J Cardiol. 2014:14:456-463.
17. Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG, et al. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol(oxf). 2008; 69: 279–284
18. Colao A, Marzullo P and Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima–media thickness in patients with acromegaly. Eur J Endocrinol. 2002;146: 303–309.
19. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014; 9: e101119.
20. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol. 2008;69(3):347–58.
21. Tellatin S, Maffei P, Osto E, Dassie F, Famoso G, Montisci R, et al. Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy. Atherosclerosis. 2017;269:100–5.
22. Amado A, Araujo F, Carvalho D. Cardiovascular Risk Factors in Acromegaly: What's the Impact of Disease Control? Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2018.
23. Wolters TLC, van der Heijden C, van Leeuwen N, HijmansKersten BTP, Netea MG, Smit JW, et al. Persistent inflammation and endothelial dysfunction in patients with treated acromegaly. Endocrine connections. 2019
24. Verhelst J, Velkeniers B, Maiter D, Haentjens P, T'Sjoen G, Rietzschel E, et al. Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. European journal of endocrinology/ European Federation of Endocrine Societies. 2013;168(2):177-84.
25. Horne BD, Anderson JL, John JM. Which white blood cell subtypes predict increased cardiovascular risk? J. Am. Coll. Cardiol. 2005; 45: 1638–1643.
26. Liu J, Du J, Fan J, Liu K, Zhang B, Wang S, et al. The Neutrophil-to-Lymphocyte Ratio Correlates with Age in Patients with Papillary Thyroid Carcinoma. ORL J Otorhinolaryngol Relat Spec. 2015; 77: 109–116
27.Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: A meta-analysis. BMC Cancer. 2014;14: 117.
28. Yue S, Zhang J, Wu J, Teng W, Liu L and Chen L. Use of the Monocyte to Lymphocyte Ratio to Predict Diabetic Retinopathy. Int. J. Environ. Res. Public Health. 2015; 12: 10009-10019
29. Bekler A, Ozkan MT, Tenekecioglu E, Gazi E, Yener AU, Temiz A, et al. Increased Platelet Distribution Width Is Associated With Severity of Coronary Artery Disease in Patients With Acute Coronary Syndrome. Angiology. 2014; 66: 63843
30. Song CS, Park DI, Yoon MY, Seok HS, Park JH, Kim HJ, et al. Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. Dig Dis Sci. 2012; 57: 1033-8
31. Arikan S, Bahceci M, Tuzcu A and Gokalp D. Serum tumour necrosis factor-alpha and interleukin-8 levels in acromegalic patients: acromegaly may be associated with moderate inflammation. Clinical Endocrinology 2009; 70: 498–501.
32. Ucler R, Aslan M, Atmaca M, Alay M, Ademoglu EN and Gulsen İ. Evaluation of blood neutrophil to lymphocyte and platelet to lymphocyte ratios according to plasma glucose status and serum insulin-like growth factor 1 levels in patients with acromegaly. Hum Exp Toxicol. 2016; 35:608-12
33. Ozkan C, Eroglu Altinova A, Cerit ET, Yayla C, Sahinarslan A, Sahin D, et al. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary. 2015; 18:621–629
34. Ucler R, Aslan M, Atmaca M, Alay M, Ademoglu EN, Candan Z et al. The effect of disease control on mean platelet volume and red blood cell distribution in patients with acromegaly. Int J Clin Exp Med. 2015; 8: 6060-6066.
35.Arpaci D, Kuzu F, Unal M, Ilikhan SU, Buyukuysal MC, Bayraktaroglu T. Assessment of Mean Platelet Volume and its Effect on Disease Control in Patients with Acromegaly. Clin Lab. 2016; 62: 2167-2171.